October 14, 2026 / By Tim Head / in Retatrutide
 What the Clinical Data Shows.jpg)
Retatrutide and semaglutide both show significant weight-loss effects, but they work differently. Retatrutide activates GIP, GLP-1, and glucagon receptors, while semaglutide primarily targets GLP-1. Clinical trials have reported greater average weight loss with retatrutide, but the studies were conducted separately. Therefore, these results cannot establish that retatrutide is more effective.
Retatrutide and semaglutide (Wegovy) are steroid treatments being investigated or used for obesity, but they act on distinct biological mechanisms. Retatrutide is a tri-receptor agonist currently being studied in a phase 3 trial, targeting GIP, GLP-1, and glucagon receptors, which may impact the safety profile of weight loss medications. Semaglutide, on the other hand, is a GLP-1 receptor agonist and the main active ingredient in Wegovy. Both steroids have shown substantial weight loss in clinical trials, although their findings are based on.
The main difference between retatrutide and semaglutide is their receptor activity.
Retatrutide: Targets GIP, GLP-1, and glucagon receptors.
Semaglutide: Primarily targets the GLP-1 receptor.
Retatrutide: Remains investigational.
Wegovy: Is an approved medicine for specific weight-management indications.
This difference in mechanism is one reason researchers are interested in retatrutide as a potential future treatment for obesity and metabolic conditions.
Retatrutide is designed to activate three hormone pathways:
GIP receptor
GLP-1 receptor
Glucagon receptor
GLP-1 activity is linked to appetite and food intake control, whereas the metabolic effects of GIP and glucagon can contribute further.
In a Phase 2 study with 338 subjects suffering from obesity or overweight along with weight-related diseases, retatrutide led to a dose-dependent decrease in weight for 48 weeks. At the highest dose, the average weight reduction was 24.2%, compared with 2.1% in the placebo group.
Semaglutide (Wegovy) mimics the GLP-1 hormone, helping reduce appetite, increase fullness, slow stomach emptying, and support weight loss.
The primary mode of action of semaglutide involves stimulation of GLP-1 receptors. This process is associated with appetite control and glucose metabolism.
The STEP 1 trial recruited 1,961 obese or overweight adults. After 68 weeks, those on weekly semaglutide 2.4 mg therapy showed a 14.9% decrease in their body weight from baseline, against 2.4% for placebo recipients.
Commonly reported side effects included:
Nausea
Diarrhea
Vomiting
Constipation
The available clinical evidence shows meaningful weight reduction with both medicines, but the studies were conducted separately.
|
Clinical factor |
Retatrutide |
Semaglutide (Wegovy) |
|
Main targets |
GIP, GLP-1, glucagon |
GLP-1 |
|
Status |
Investigational |
Approved medicine |
|
Key study |
Phase 2 |
STEP 1 |
|
Study duration |
48 weeks |
68 weeks |
|
Reported weight reduction |
Up to 24.2% |
14.9% |
|
Clinical evidence |
Developing |
Established |
These numbers should not be interpreted as proof that retatrutide is directly more effective because the participants, study designs, treatment periods, and trial conditions were different.
Early clinical research suggests retatrutide may produce greater weight loss than semaglutide, but direct comparisons are limited. Retatrutide is still investigational, so more research is needed to confirm its long-term effectiveness and safety.
The trials of Retatrutide have yielded significant weight loss, even higher in late-stage trials. Nevertheless, clinical trials carried out separately cannot yield evidence to the same extent as a head-to-head trial.
A proper comparison would evaluate both medicines:
In the same set of patients
During equal periods of treatment
Under equal experimental conditions
With equal outcome measures
With similar safety observations
Therefore, the existing data can show what each medicine achieved in its own trials, but it cannot establish a definitive head-to-head winner.
Both medicines have demonstrated significant weight-loss effects in clinical research.
Phase 2 trial demonstrated that there was up to 24.2% mean weight loss after 48 weeks using the maximum dose tested.
According to the STEP 1 study, weight loss following treatment with semaglutide 2.4 mg is 14.9% after 68 weeks
When comparing these figures, readers should consider:
Varied study populations
Varied trial periods
Varied dosages
Varied study designs
Varied baselines
This is especially true when examining a product or claim presented through online sources, such as Online UK Steroid Shop. An item or claim presented online does not provide the same level of evidence as a controlled clinical trial or regulatory approval.
No. Retatrutide is an investigational steroid undergoing clinical trial testing. This point is crucial since investigational products have yet to undergo the same approval process as approved steroids.
Wegovy contains semaglutide and is approved for weight management. The steroid has undergone clinical trials to prove its efficacy and safety.
Not from the individual trials results obtained separately and independently. This is because a comparative study can only be done through a head-to-head clinical trial. There are some weaknesses with cross-trial comparison studies.
The most relevant factors include:
Participant characteristics
Treatment duration
Dose
Study design
Placebo group
Primary endpoints
Adverse-event reporting
Retatrutide acts on three receptors: GIP, GLP-1, and glucagon.
Semaglutide acts on the GLP-1 receptor.
Retatrutide is currently under investigation.
Wegovy contains semaglutide and has been approved by the regulatory agency.
Both steroids have shown considerable weight loss in clinical trials.
Results from both trials cannot be compared directly.
No. Retatrutide targets GIP, GLP-1, and glucagon receptors, while semaglutide primarily targets the GLP-1 receptor.
Separate clinical trials have reported larger average weight reductions with retatrutide, but these studies were not direct head-to-head comparisons.
What are the key differences between retatrutide and semaglutide?
Semaglutide acts on one hormone receptor GLP-1 and has been approved by the FDA, while Retatrutide acts on three hormone receptors (GLP-1, GIP, and glucagon).
No. Retatrutide remains an investigational medicine undergoing clinical evaluation.
Two medicines used for weight management are retatrutide and semaglutide. While retatrutide targets three receptor mechanisms and results in significant weight loss, semaglutide boasts of an extensive clinical history. The current literature offers a wealth of information concerning both steroids. Nonetheless, individual studies of each steroid differ; therefore, approach weight-loss percentages with caution. A comparative study will offer more convincing proof of the effectiveness of the two steroids.
I am a urologist with a focus on kidney transplants and urological surgery. My work involves treating patients with kidney and urinary conditions and providing careful, evidence-based guidance. I also study how anabolic steroids affect the body, especially in bodybuilding, to help people understand their real health impacts and make informed decisions.
